Misplaced Pages

Pingyangmycin: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 22:24, 14 October 2012 editLilHelpa (talk | contribs)Extended confirmed users, Pending changes reviewers413,676 editsm it's -> its using AWB← Previous edit Revision as of 19:23, 12 February 2013 edit undoRjwilmsi (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers932,085 editsm Typo fixing, typos fixed: varities → varieties using AWB (8906)Next edit →
Line 36: Line 36:
'''Pingyangmycin''' (also known as '''Bleomycin A<sub>5</sub>''') is an ] ] belongs to ], which is produced by ''Streptomyces verticillus var. pingyangensis n.sp.'', a ] of '']''. It was discovered in 1969 at ] of ] in ], and was brought into clinical use in 1978.<ref>{{Cite journal | last1 = Lin | first1 = F. T. | last2 = Li | first2 = D. D. | last3 = Yang | first3 = X. P. | last4 = Li | first4 = Q. | last5 = Xue | first5 = Y. C. | last6 = Zhen | first6 = Y. S. | title = Antitumor activity and preclinical pharmacologic evaluation of pingyangmycin (author's transl) | journal = Zhonghua zhong liu za zhi &#92;Chinese journal of oncology&#93; | volume = 1 | issue = 3 | pages = 161–166 | year = 1979 | pmid = 95444}}</ref> '''Pingyangmycin''' (also known as '''Bleomycin A<sub>5</sub>''') is an ] ] belongs to ], which is produced by ''Streptomyces verticillus var. pingyangensis n.sp.'', a ] of '']''. It was discovered in 1969 at ] of ] in ], and was brought into clinical use in 1978.<ref>{{Cite journal | last1 = Lin | first1 = F. T. | last2 = Li | first2 = D. D. | last3 = Yang | first3 = X. P. | last4 = Li | first4 = Q. | last5 = Xue | first5 = Y. C. | last6 = Zhen | first6 = Y. S. | title = Antitumor activity and preclinical pharmacologic evaluation of pingyangmycin (author's transl) | journal = Zhonghua zhong liu za zhi &#92;Chinese journal of oncology&#93; | volume = 1 | issue = 3 | pages = 161–166 | year = 1979 | pmid = 95444}}</ref>


In China pingyangmycin has largely superseded bleomycin A<sub>2</sub> (commonly known as "bleomycin"), since it is more effective, costs less, is easier to get, can treat a larger varities of ]s (such as ] and ]) and causes less ] injury.<ref>{{Cite journal | last1 = Zheng | first1 = J. W. | last2 = Yang | first2 = X. J. | last3 = Wang | first3 = Y. A. | last4 = He | first4 = Y. | last5 = Ye | first5 = W. M. | last6 = Zhang | first6 = Z. Y. | doi = 10.1016/j.oraloncology.2009.02.011 | title = Intralesional injection of Pingyangmycin for vascular malformations in oral and maxillofacial regions: An evaluation of 297 consecutive patients | journal = Oral Oncology | volume = 45 | issue = 10 | pages = 872–876 | year = 2009 | pmid = 19628423| pmc = }}</ref><ref>{{Cite journal | last1 = Xu | first1 = H. Z. | last2 = Zhang | first2 = H. Y. | title = The isolation and identification of pingyangmycin (author's transl) | journal = Yao xue xue bao = Acta pharmaceutica Sinica | volume = 15 | issue = 10 | pages = 609–614 | year = 1980 | pmid = 6167140}}</ref> Even though it also results in ], unlike bleomycin, its most serious ] is ], which is rare but may happen even in a low dose, and can be fatal.<ref>{{Cite journal | last1 = Shou | first1 = B. Q. | last2 = Mao | first2 = Z. | last3 = Zhang | first3 = S. L. | last4 = Yang | first4 = Z. | title = Allergy caused by minidose and low concentration Pingyangmycin: A case report | journal = Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology | volume = 27 | issue = 5 | pages = 572–573 | year = 2009 | pmid = 19927737}}</ref> Besides, it causes more ] than bleomycin: the occurrence of this complication in patients is between 20% and 50%. In China pingyangmycin has largely superseded bleomycin A<sub>2</sub> (commonly known as "bleomycin"), since it is more effective, costs less, is easier to get, can treat a larger varieties of ]s (such as ] and ]) and causes less ] injury.<ref>{{Cite journal | last1 = Zheng | first1 = J. W. | last2 = Yang | first2 = X. J. | last3 = Wang | first3 = Y. A. | last4 = He | first4 = Y. | last5 = Ye | first5 = W. M. | last6 = Zhang | first6 = Z. Y. | doi = 10.1016/j.oraloncology.2009.02.011 | title = Intralesional injection of Pingyangmycin for vascular malformations in oral and maxillofacial regions: An evaluation of 297 consecutive patients | journal = Oral Oncology | volume = 45 | issue = 10 | pages = 872–876 | year = 2009 | pmid = 19628423| pmc = }}</ref><ref>{{Cite journal | last1 = Xu | first1 = H. Z. | last2 = Zhang | first2 = H. Y. | title = The isolation and identification of pingyangmycin (author's transl) | journal = Yao xue xue bao = Acta pharmaceutica Sinica | volume = 15 | issue = 10 | pages = 609–614 | year = 1980 | pmid = 6167140}}</ref> Even though it also results in ], unlike bleomycin, its most serious ] is ], which is rare but may happen even in a low dose, and can be fatal.<ref>{{Cite journal | last1 = Shou | first1 = B. Q. | last2 = Mao | first2 = Z. | last3 = Zhang | first3 = S. L. | last4 = Yang | first4 = Z. | title = Allergy caused by minidose and low concentration Pingyangmycin: A case report | journal = Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology | volume = 27 | issue = 5 | pages = 572–573 | year = 2009 | pmid = 19927737}}</ref> Besides, it causes more ] than bleomycin: the occurrence of this complication in patients is between 20% and 50%.


==References== ==References==

Revision as of 19:23, 12 February 2013

Pharmaceutical compound
Pingyangmycin
Clinical data
Pregnancy
category
  • D
Routes of
administration		intravenous, intraarterial, intramuscular, intratumoral
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Metabolismamidase
Elimination half-life1.3 hours
Excretionrenal (25-50%)
Identifiers
IUPAC name
  • -3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3--1,3-thiazol-2-yl]-1,3-thiazol-2-yl]ethylamino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-4-methyl-5-oxopentan-2-yl]amino]-1-(1H-imidazol-5-yl)-3-oxopropoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl] carbamate
CAS Number
PubChem CID
ChemSpider
ECHA InfoCard100.031.221 Edit this at Wikidata
Chemical and physical data
FormulaC57H89N19O21S2
Molar mass1440.56126 g·mol
3D model (JSmol)
SMILES
  • CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCCNCCCCN)O
InChI
  • InChI=1S/C57H89N19O21S2/c1-22-35(73-48(76-46(22)61)27(14-33(60)80)68-15-26(59)47(62)86)52(90)75-37(43(28-16-65-21-69-28)95-56-45(41(84)39(82)31(17-77)94-56)96-55-42(85)44(97-57(63)92)40(83)32(18-78)93-55)53(91)70-24(3)38(81)23(2)49(87)74-36(25(4)79)51(89)67-13-8-34-71-30(20-98-34)54-72-29(19-99-54)50(88)66-12-7-11-64-10-6-5-9-58/h16,19-21,23-27,31-32,36-45,55-56,64,68,77-79,81-85H,5-15,17-18,58-59H2,1-4H3,(H2,60,80)(H2,62,86)(H2,63,92)(H,65,69)(H,66,88)(H,67,89)(H,70,91)(H,74,87)(H,75,90)(H2,61,73,76)
  • Key:QYOAUOAXCQAEMW-UHFFFAOYSA-N

Pingyangmycin (also known as Bleomycin A5) is an antitumor glycopeptide antibiotic belongs to bleomycin, which is produced by Streptomyces verticillus var. pingyangensis n.sp., a variety of Streptomyces verticillus. It was discovered in 1969 at Pingyang County of Zhejiang Province in China, and was brought into clinical use in 1978.

In China pingyangmycin has largely superseded bleomycin A2 (commonly known as "bleomycin"), since it is more effective, costs less, is easier to get, can treat a larger varieties of cancers (such as breast cancer and liver cancer) and causes less lung injury. Even though it also results in pulmonary fibrosis, unlike bleomycin, its most serious side effect is anaphylactic shock, which is rare but may happen even in a low dose, and can be fatal. Besides, it causes more fever than bleomycin: the occurrence of this complication in patients is between 20% and 50%.

References

  1. Lin, F. T.; Li, D. D.; Yang, X. P.; Li, Q.; Xue, Y. C.; Zhen, Y. S. (1979). "Antitumor activity and preclinical pharmacologic evaluation of pingyangmycin (author's transl)". Zhonghua zhong liu za zhi \Chinese journal of oncology]. 1 (3): 161–166. PMID 95444.{{cite journal}}: CS1 maint: extra punctuation (link)
  2. Zheng, J. W.; Yang, X. J.; Wang, Y. A.; He, Y.; Ye, W. M.; Zhang, Z. Y. (2009). "Intralesional injection of Pingyangmycin for vascular malformations in oral and maxillofacial regions: An evaluation of 297 consecutive patients". Oral Oncology. 45 (10): 872–876. doi:10.1016/j.oraloncology.2009.02.011. PMID 19628423.
  3. Xu, H. Z.; Zhang, H. Y. (1980). "The isolation and identification of pingyangmycin (author's transl)". Yao xue xue bao = Acta pharmaceutica Sinica. 15 (10): 609–614. PMID 6167140.
  4. Shou, B. Q.; Mao, Z.; Zhang, S. L.; Yang, Z. (2009). "Allergy caused by minidose and low concentration Pingyangmycin: A case report". Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology. 27 (5): 572–573. PMID 19927737.
Categories: